AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6120717
Drug: Lormetazepam (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam (0.5, 1.0, and 2.0 mg)
Trial: 6120717
Drug: Camazepam (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camazepam (10-20 mg)
Trial: 15068402
Drug: Methylphenidate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (1 mg/kg/day)
Trial: 15000770
Drug: Innovo insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Innovo insulin doser
Trial: 7972311
Drug: Control (diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (diltiazem 120 mg orally without grapefruit juice)
Trial: 2657428
Drug: Prednisone, 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone, 0.75 mg/kg/day (n = 33)
Trial: 2657428
Drug: Prednisone, 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone, 1.5 mg/kg/day (n = 34)
Trial: 2657428
Drug: High-dose prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prednisone (1.5 mg/kg/day)
Trial: 30726692
Drug: Omadacycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omadacycline (100 mg intravenously every 12 hours for two doses, then 100 mg intravenously every 24 hours; transition to oral 300 mg every 24 hours after 3 days)
Trial: 30726692
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg intravenously every 24 hours; transition to oral 400 mg every 24 hours after 3 days)
Trial: 26482031
Drug: Negative-pressure incision
RxNorm normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative-pressure incision therapy device applied for 5-7 days
Trial: 22429618
Drug: Topical mydriatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mydriatics (TM) - cyclopentolate 0.85%, phenylephrine 1.5%, xylocaine 1% intracamerally
Trial: 17389556
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch (10-cm², 18 mg) applied to upper back
Trial: 17389556
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch (10-cm², 18 mg) applied to chest
Trial: 17389556
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch (10-cm², 18 mg) applied to abdomen
Trial: 17389556
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch (10-cm², 18 mg) applied to thigh
Trial: 17389556
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch (10-cm², 18 mg) applied to upper arm
Trial: 11875330
Drug: HRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT with 2 mg estradiol valerate and 1 mg cyproterone acetate (n = 15)
Trial: 11875330
Drug: HRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT with 2 mg estradiol valerate and 75 mug levonorgestrel (n = 15)
Trial: 2125460
Drug: Betaxolol 20
RxNorm normalized name: betaxolol 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 20 mg daily
Trial: 6775297
Drug: Lénitral 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lénitral 2.5 mg (2 capsules)
Trial: 6775297
Drug: Lénitral 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lénitral 7.5 mg (1 capsule)
Trial: 6775297
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin 0.6 mg
Trial: 21867540
Drug: Corticosteroid infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corticosteroid infusion
Trial: 17302019
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or conservative treatment
Trial: 15197664
Drug: E-5564, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-5564, an injectable endotoxin antagonist
Trial: 11325088
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine (15-30 mg IV q 6 h)
Trial: 9215655
Drug: Reverse transcriptase
RxNorm normalized name: Reverse transcriptase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reverse transcriptase inhibitor therapy
Trial: 3322728
Drug: 50% reduction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% reduction in intermediate‐acting insulin dose
Trial: 3322728
Drug: 50% reduction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% reduction in soluble insulin dose
Trial: 18657667
Drug: Eplerenone, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone, 100 mg daily (n = 33)
Trial: 18657667
Drug: Eplerenone, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone, 100 mg daily
Trial: 2663800
Drug: Testolactone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testolactone (2 g/day)
Trial: 28716314
Drug: Ebselen 400
RxNorm normalized name: Ebselen
DrugBank: Ebselen (DB12610)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebselen 400 mg
Trial: 28716314
Drug: Ebselen 200
RxNorm normalized name: Ebselen
DrugBank: Ebselen (DB12610)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebselen 200 mg
Trial: 28716314
Drug: Ebselen 600
RxNorm normalized name: Ebselen
DrugBank: Ebselen (DB12610)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebselen 600 mg
Trial: 23223314
Drug: Sirolimus (4-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (4-10 ng/mL) and prednisolone 5 mg/day
Trial: 20926750
Drug: Clazosentan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazosentan (1 mg/h continuous intravenous infusion for 6 hours)
Trial: 18097226
Drug: Structured treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured treatment interruption (STI)
Trial: 10423615
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg corn-oil suspension
Trial: 10423615
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg corn-oil suspension
Trial: 10423615
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg corn-oil suspension
Trial: 10423615
Drug: Osteofix tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteofix tablet
Trial: 8175218
Drug: Captopril pretreatment
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril pretreatment (6.25 mg orally about 15 min before thrombolysis) in Group A
Trial: 8175218
Drug: Captopril late-treatment
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril late-treatment (administered about 3 days after thrombolysis) in Group B
Trial: 8175218
Drug: Captopril late-treatment
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril late-treatment in Group B
Trial: 3431098
Drug: Quik Test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quik Test Drug Screen for detection of benzoylecgonine
Trial: 3431098
Drug: Quik Test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quik Test Drug Screen for benzoylecgonine
Trial: 30172948
Drug: β1-preferential antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: β1-preferential antagonist (10 mg bisoprolol)
Trial: 30172948
Drug: Non-preferential β1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-preferential β1 + β2-antagonist (80 mg nadolol)
Trial: 23879079
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (220 mg zinc sulfate daily)
Trial: 20337616
Drug: New anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New anaesthetic drug administration system
Trial: 16427266
Drug: Ciclesonide 320
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide 320 microg once daily via HFA-MDI without a spacer
Trial: 16427266
Drug: Budesonide 320
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 320 microg once daily
Trial: 10823524
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) 2 microg/kg subcutaneously once a day for 5 days
Trial: 1730830
Drug: Histamine diphosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine diphosphate (0.01 mg/ml)
Trial: 1730830
Drug: Histamine diphosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine diphosphate (0.05 mg/ml)
Trial: 1730830
Drug: Histamine diphosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine diphosphate (dose-response curve)
Trial: 24339234
Drug: XP21279-carbidopa (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP21279-carbidopa (3 times daily)
Trial: 24339234
Drug: Immediate-release carbidopa-levodopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release carbidopa-levodopa (4 or 5 times daily)
Trial: 11372005
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (0.3 mmol/kg/h)
Trial: 9416716
Drug: 2 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 microg/kg oral clonidine
Trial: 9416716
Drug: 4 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 microg/kg oral clonidine
Trial: 8480273
Drug: Allopurinol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (50 mg, orally, four times a day)
Trial: 8480273
Drug: DMSO (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMSO (500 mg, orally, four times a day)
Trial: 25321394
Drug: danoprevir 100
RxNorm normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: danoprevir 100 mg twice daily
Trial: 25321394
Drug: danoprevir 200
RxNorm normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: danoprevir 200 mg three times daily
Trial: 25321394
Drug: danoprevir 300
RxNorm normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: danoprevir 300 mg twice daily
Trial: 25321394
Drug: danoprevir (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: danoprevir (various doses)
Trial: 19922626
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 or 40 mg once daily
Trial: 15521346
Drug: 0.2% Nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% Nitroglycerin ointment (0.75 mg)
Trial: 15521346
Drug: 0.4% Nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% Nitroglycerin ointment (1.5 mg)
Trial: 15521346
Drug: 0% Nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0% Nitroglycerin ointment (placebo)
Trial: 12855921
Drug: Transdermal ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal ketoprofen
Trial: 11744583
Drug: Placebo tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tape treatment (control group)
Trial: 9250445
Drug: Snack (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snack (240 ml of 2% milk plus one slice of toast, approximately 200 kcal)
Trial: 9250445
Drug: Alanine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alanine (40 g, plus 10 g of glucose, approximately 200 kcal)
Trial: 3436157
Drug: Bezafibrate (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (600 mg/day) with glibenclamide (5 to 15 mg/day)
Trial: 3436157
Drug: Fenofibrate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (300 mg/day) with glibenclamide (5 to 15 mg/day)
Trial: 3436157
Drug: Bezafibrate (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (600 mg/day) with chlorpropamide (250 to 500 mg/day)
Trial: 3436157
Drug: Fenofibrate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (300 mg/day) with chlorpropamide (250 to 500 mg/day)
Trial: 27317442
Drug: Tedizolid 300
RxNorm normalized name: Tedizolid
DrugBank: Tedizolid (DB14569)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tedizolid 300 mg once daily
Trial: 27317442
Drug: Tedizolid 400
RxNorm normalized name: Tedizolid
DrugBank: Tedizolid (DB14569)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tedizolid 400 mg once daily
Trial: 27317442
Drug: Linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg twice daily
Trial: 27317442
Drug: Tedizolid 200
RxNorm normalized name: tedizolid 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tedizolid 200 mg once daily
Trial: 22627991
Drug: Candesartan (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (7 days treatment)
Trial: 18976976
Drug: Concurrent hysterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent hysterectomy
Trial: 11521797
Drug: 5-day chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day chemotherapy regimen with Mitomycin C 12 mg/m2 day 1 and 5‐fluorouracil 500 mg/m2/24 hours for five days during weeks one and four of radiotherapy
Trial: 11521797
Drug: 7-day chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day chemotherapy regimen with Mitomycin C 12 mg/m2 day 1 and 5‐fluorouracil 500 mg/m2/24 hours for seven days during weeks one and four of radiotherapy
Trial: 11521797
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (chemoradiotherapy)
Trial: 2662291
Drug: Oxitropium bromide
RxNorm normalized name: oxitropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxitropium bromide (0.1 mg/puff, 2 puffs t.d.s. for 4 weeks)
Trial: 27681767
Drug: Maximum dose
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum dose of radiation therapy (RT)
Trial: 24520780
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine (CM) intervention (Jianpi Shugan Recipe)
Trial: 22093579
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg subcutaneously every other week for 12 weeks
Trial: 11117863
Drug: Conventional radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional radiation therapy (50 Gy in 25 fractions)
Trial: 11117863
Drug: Conventional radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional radiation plus brachytherapy boost (minimum peripheral tumor dose of 60 Gy)
Trial: 11117863
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (Conventional radiation therapy and Conventional radiation plus brachytherapy boost)
Trial: 1428296
Drug: L-alpha-glycerylphosphorylcholine (alpha-GPC)
RxNorm normalized name: L-alpha-Glycerophosphorylcholine
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-alpha-glycerylphosphorylcholine (alpha-GPC) 1,000 mg
Trial: 1428296
Drug: Citicoline (CTC)
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (CTC) 1,000 mg
Trial: 6429319
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral metoprolol (beta-blockade)
Trial: 27004617
Drug: 2 portions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 portions of fruit and vegetable (FV) daily for 12 weeks
Trial: 27004617
Drug: 4 portions
RxNorm normalized name: nonoxynol-9
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 portions of fruit and vegetable (FV) daily for 12 weeks
Trial: 27004617
Drug: 7 portions
RxNorm normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 portions of fruit and vegetable (FV) daily for 12 weeks
Trial: 20445490
Drug: Gel-lubricated non-hydrophilic
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel-lubricated non-hydrophilic catheter
Trial: 17328985
Drug: Peg-IFNalpha monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg-IFNalpha monotherapy (180 microg weekly)
Trial: 17328985
Drug: Peg-IFNalpha and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg-IFNalpha and ribavirin (up to maximum tolerated dose for 48 weeks)
Trial: 8381164
Drug: Early thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early thoracic irradiation (TI) - 40 Gy in 15 fractions over 3 weeks concurrent with the first cycle of etoposide and cisplatin (EP) (week 3)
Trial: 8381164
Drug: Late thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late thoracic irradiation (TI) - 40 Gy in 15 fractions over 3 weeks concurrent with the last cycle of etoposide and cisplatin (EP) (week 15)
Trial: 4898563
Drug: Hexoestrol, 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexoestrol, 45 mg, single injection
Trial: 4898563
Drug: Stilboestrol, customary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stilboestrol, customary oral course
Trial: 31141275
Drug: Body lotion
RxNorm normalized name: LOBANA BODY LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body lotion with 3HFWC
Trial: 31141275
Drug: Body lotion
RxNorm normalized name: LOBANA BODY LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body lotion vehiculum (control)
Trial: 31141275
Drug: Hand cream
RxNorm normalized name: TETRIX HAND CREAM,TOP
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hand cream with 3HFWC
Trial: 31141275
Drug: Commercial hand
RxNorm normalized name: ALCOHOL 70 mL in 100 TOPICAL CLOTH [Amazon Commercial Hand Sanitizer Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial hand cream (control)
Trial: 26508709
Drug: Ivabradine (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine (2.5, 5, or 7.5 mg bid)
Trial: 24113671
Drug: Lower-dose diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose diclofenac submicron particle capsules 35 mg TID
Trial: 24113671
Drug: Lower-dose diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose diclofenac submicron particle capsules 18 mg TID
Trial: 15304586
Drug: Acetaminophen 500
RxNorm normalized name: acetaminophen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500 mg before and 6 and 12 hours after each injection
Trial: 15304586
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg before and 6 and 12 hours after each injection
Trial: 15304586
Drug: Prednisone 60
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 60 mg daily for 1 week, plus tapering
Trial: 11182530
Drug: Active nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active nicotine patches (N = 18)
Trial: 11182530
Drug: Placebo patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches (N = 20)
Trial: 9217952
Drug: Successful amnioinfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful amnioinfusion (infused solution alleviated oligohydramnios for > 48 hours)
Trial: 9217952
Drug: Unsuccessful amnioinfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsuccessful amnioinfusion (infused solution rapidly lost)
Trial: 3110524
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg RO 15-1788
Trial: 3110524
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg RO 15-1788
Trial: 3110524
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg RO 15-1788
Trial: 28782145
Drug: Camicinal 150
RxNorm normalized name: Camicinal
DrugBank: Camicinal (DB12567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camicinal 150 mg
Trial: 27439601
Drug: Intracoronary autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary autologous bone marrow cell (BMC) infusion
Trial: 27439601
Drug: State-of-the-art therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: State-of-the-art therapy (control group)